Quantcast

Latest NT-501 Stories

2009-05-28 07:32:00

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which...

2008-09-04 12:00:33

Neurotech Pharmaceuticals, a biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, has announced that the FDA has granted fast track designations for NT-501 for the treatment of visual loss in two indications - retinitis pigmentosa and the dry form of age-related macular degeneration. Neurotech is conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with retinitis pigmentosa (RP)-one consisting of...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related